Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MGD024

Bispecific antibody · Immune activation, directed at CD123 (interleukin-3 receptor alpha chain) (IL3RA) and CD3 (CD3E) · developed by MacroGenics

Phase 1 Most advanced trial
MGNX Developer
1 Registered trials

What is MGD024?

MGD024 is a DART bispecific antibody-like protein that binds CD123, the interleukin-3 receptor alpha chain, on cancer cells and CD3 on T cells. By crosslinking the two, it activates T cells and drives cytotoxic T-lymphocyte killing of CD123-expressing cells. It is studied in hematologic malignancies including acute myeloid leukemia, myelodysplastic syndromes and Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
CD123 (interleukin-3 receptor alpha chain) (IL3RA), CD3 (CD3E)
Mechanism
Immune activation, directed at CD123 (interleukin-3 receptor alpha chain) (IL3RA) and CD3 (CD3E)
Pathways
T-cell activation and proliferation, CTL-mediated cell lysis
Therapy area
Oncology
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05362773 Phase 1 Leukemia, Acute Myeloid Active not recruiting MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Blastic Plasmacytoid Dendritic Cell NeoplasmChronic Myeloid LeukemiaClassical Hodgkin LymphomaLeukemia, Acute MyeloidLeukemia, B-cellLeukemia, Hairy CellMastocytosis, Aggressive SystemicMyelodysplastic Syndromes

Other drugs acting on IL3RA / CD3E

More from MacroGenics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind MGD024

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.